Fundamental Analysis (FA)
Framework: DCF Benchmarked
Join Palmy To Bypass The Blur →
For XRX
Valuation Somewhat Weak
43%
Profitability n.A.
Fin. Growth Positive
67%
Leverage & Liquidity Weak
33%
Per Share Metrics Weak
33%
Fin. Health n.A.
Fundamental Analysis (FA)
Benchmarked
1 Financial Health
Metric Q4 Q1 Δ in %
Current Ratio 20.12 1.37 1.14
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA 273.87 72.50 19.39
Naive Interpretation member
2 Per Share
Metric Q4 Q1 Δ in %
Book Value -6.47 20.92 22.36
Cash 25.61 6.01 4.79
Capex 0.69 -0.08 -0.08
Free Cash Flow -76.68 -0.72 3.08
Revenue -15.49 12.12 14.34
Naive Interpretation member
3 Profitability
Metric Q4 Q1 Δ in %
Gross Margin -15.80 0.28 0.33
Operating Margin -76.77 -0.01 0.05
ROA -96.08 -0.01 < 0.005
ROE -106.85 -0.04 -0.02
ROIC -78.01 < 0.005 < 0.005
Naive Interpretation member
4 Valuation
The "Valuation Entry" for the Focus of XRX is permitted for members.
5 Growth
The "Growth Entry" for the Focus of XRX is permitted for members.
6 Leverage & Liquidity
The "Leverage & Liquidity Entry" for the Focus of XRX is permitted for members.